Antipsychotic medications are widely prescribed for behavioral and psychological symptoms in dementia despite limited efficacy and significant harms including increased mortality. A systematic approach to deprescribing—identifying and discontinuing unnecessary antipsychotics—represents a critical intervention to improve safety and quality of life in this population.
Key Points
- Antipsychotics show minimal efficacy for dementia behavioral symptoms
- These drugs carry substantial mortality and adverse event risks
- Deprescribing protocols can safely reduce or eliminate antipsychotic use
Longevity Analysis
The prescription of antipsychotics in dementia exemplifies how pharmacological intervention can create greater harm than benefit when applied without adequate evidence. In older adults with cognitive decline, these drugs compromise nervous system function, increase cardiovascular risk, and accelerate deterioration—mechanisms that directly undermine longevity. A deprescribing approach requires first identifying what interferes with health (unnecessary medication), then decoding the actual drivers of behavioral symptoms, which are often rooted in unmet physical or environmental needs rather than dopaminergic dysregulation. This shift from automatic prescription to intentional deprescribing reflects a fundamental principle of sustainable health optimization: sometimes the most powerful intervention is knowing what to stop.
Original published by The Lancet Healthy Longevity, by Rosa Liperoti, Graziano Onder.